Posted by Michael Wonder on 22 Jun 2024
Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi
20 June 2024 - Agreement includes access to any future licence extensions.
Vertex Pharmaceuticals today announced an extended long-term reimbursement agreement with NHS England providing access to Kaftrio (elexacaftor with tezacaftor and ivacaftor), Symkevi (tezacaftor with ivacaftor) and Orkambi (lumacaftor with ivacaftor) for all existing and future eligible cystic fibrosis patients in England.
